Christine joined NEA as an associate on the healthcare team in 2019. Prior to joining NEA, Christine was a member of the Barclays healthcare investment banking group, where she focused on M&A and equity deals across biopharma and healthcare services, including transactions for CRISPR Therapeutics and Nightstar/Biogen as well as Merck’s acquisition of Antelliq and Seattle Genetics’ acquisition of Cascadian.
Christine graduated from the Roy and Diana Vagelos Program at the University of Pennsylvania, where she earned a B.A. in Biology from the College of Arts and Sciences and a B.S. in Economics from the Wharton School. During her time in college, she co-founded a technology-enabled care coordination platform for health systems across the Northeast to provide transportation assistance for their patients.